Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

47
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
47
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

294
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
294
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

5.4K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa.

Journal of comparative effectiveness research·2026
Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same author

Structure, Electrochemistry, and Phase Evolution of Al-Substituted Na<sub>2/3</sub>[Ni<sub>1/3‑y</sub>Mn<sub>2/3‑z</sub>Al <sub><i>y</i>+<i>z</i></sub> ]O<sub>2</sub> as a Sodium-Ion Battery Cathode Material.

Chemistry of materials : a publication of the American Chemical Society·2026
Same author

Multimodal phenotypic clustering predicts cardiac outcomes in Fabry disease.

Orphanet journal of rare diseases·2026
Same author

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Orphanet journal of rare diseases·2026
Same author

A cost-based-plus pricing approach for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome.

Orphanet journal of rare diseases·2026

Related Experiment Video

Updated: Mar 5, 2026

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

649

Enzyme replacement and substrate reduction therapy for Gaucher disease.

Elad Shemesh1, Laura Deroma, Bruno Bembi

  • 1Israel Defense Forces Medical Corps, Haifa, Israel.

The Cochrane Database of Systematic Reviews
|March 28, 2015
PubMed
Summary

This review found that enzyme replacement therapies for Gaucher disease (GD) show similar efficacy and safety in the first year. Lower doses of enzyme replacement therapy (ERT) are as effective as higher doses for Gaucher disease clinical outcomes.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

8.6K
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K

Related Experiment Videos

Last Updated: Mar 5, 2026

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

649
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

8.6K
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K

Area of Science:

  • Rare disease research
  • Genetic disorders
  • Metabolic diseases

Background:

  • Gaucher disease (GD) is an ultra-orphan disorder caused by glucocerebrosidase deficiency.
  • Four treatments are approved for Gaucher disease, but limited randomized controlled trials (RCTs) exist.
  • This study systematically evaluated available RCT data on GD treatments.

Purpose of the Study:

  • To summarize RCT data on the efficacy and safety of enzyme replacement therapies (ERT) and substrate reduction therapy (SRT) for Gaucher disease.
  • To assess treatment responses based on hemoglobin, platelet count, organ volume, and biomarkers.

Main Methods:

  • Searched multiple databases including Cochrane, ClinicalTrials.gov, and PubMed for RCTs.
  • Included all randomized and quasi-randomized controlled studies of ERT or SRT for all types of Gaucher disease.
  • Two authors independently assessed risk of bias and extracted data from eight included studies (300 participants).

Main Results:

  • Different recombinant glucocerebrosidases showed similar efficacy and safety in the first year of treatment for Gaucher disease.
  • Lower ERT doses (30-45 units/kg) were as effective as higher doses (60 units/kg) for clinical outcomes.
  • Miglustat (SRT) showed comparable efficacy to ERT for maintenance therapy in type 1 Gaucher disease.

Conclusions:

  • Analysis of limited RCTs highlights challenges in rare disease research.
  • Different ERTs are bio-similar and non-inferior in safety and efficacy for Gaucher disease during the first year.
  • Innovative trial designs are needed for long-term efficacy and safety data in chronic rare diseases like Gaucher disease.